Annegret Van der Aa, PhD has a broad R&D experience in small and mid-size biotech (Innogenetics, ActoGeniX, OCTIMET Oncology, and Galapagos) for nearly 20 years.
Annegret is an immunologist by training with a PhD obtained at Hasselt University.
Subsequently, she took up increasing responsibilities in various R&D positions covering the full spectrum from research to up late clinical development. This included managing a research group, compound strategic and operational leadership to building a clinical development/operations department which resulted in the transitioning of more than 10 preclinical candidates to clinical stage products.
Moreover, Annegret has deep scientific and operational expertise and built a broad network over the past 20 years in the field of auto-immune and chronic inflammatory diseases.
At Galapagos, she has been instrumental in the clinical development of Jyseleca® (filgotinib), which was approved for a first indication in 2020.